Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
48-page U.S STUDY ON MARINE ENERGY POTENTIAL. Lots of technical jargon but one can see the huge potential given the right technology to harness that energy.
https://www.energy.gov/sites/prod/files/2021/02/f82/78773_3.pdf
“Marine energy resources are predictable sources of renewable energy. They are distributed broadly across the world’s oceans, along its coastlines, and throughout the world’s rivers. As the demand for renewable energy technologies continues to grow, marine energy resources have the potential to contribute meaningfully to the U.S. and world energy supply.”
if energy storage technologies become sufficiently inexpensive, it does raise the possibility that OTEC—and other marine energy resources that are distant from load centers (e.g., wave energy along Alaska’s Aleutian Island chain)—become viable sources of energy. Harnessing 1% of this resource, assuming a capacity factor of 100%, would mean installing 5.3 GW of OTEC capacity9—energy sufficient to power more than 4-million homes.
Obvious pump and dump. News put out by MYSZ. Not exactly unbiased. The FOMO crowd is about to get taught a painful lesson.
why is CGuard not approved in the U.S. and approved all over the ROW. Has it been rejected by the FDA? If so when and why? Plans to resubmit?
Idiot who says company has one employee. See Yahoo finance profile.
TimefireVR Inc.
Building A
Suite 100
Scottsdale, AZ 85260
United States
480-663-8118
http://www.timefirevr.comSector: ;
Industry:
Full Time Employees: 30
Power supply is the biggest issue going forward for crypto mining. Extraordinary sources of reliable power will be needed.
https://cointelegraph.com/news/digital-currency-mining-may-look-much-different-in-2025
Let's say that CYTR drugs are equally or slightly better than the competition. The fact that people can get higher doses of CYTR chemotherapy with fewer adverse events AND NO HAIR LOSS IS HUGE BY ITSELF.
https://docs.google.com/document/d/1BM0-mFHwHREM8P4cstHT50wUlCopzw4CxaEzwXRIvGc/edit
Best overview and buyout scenario. Page 15. Price target $10-$30!!
The company forecasts $42M in revenues in 2017, and nearing break-even in 4Q 2017. Company officials assert that they are well-funded through the end of 2019.
Robert S. Rahimi, M.D., MSCR, Transplant Hepatologist at Baylor Scott and White Health Care System and a lead investigator of the STOP-HE study, commented, “OCR-002 showed important benefit over the standard of care (a decades-old laxative) which could allow for a significant shift in the treatment paradigm. I’m equally excited about Ocera’s companion tablet form of the drug in development for chronic use. I believe OCR-002 could be a game changer in the management of HE,” added Dr. Rahimi.
so we are going from 14 million to to 16 million outstanding shares. No biggy. Insiders still own about 50% of shares and a lot of the remaining shares are owned by institutions. Sell off is way over blown and I am loading in the $2.50's
New to this stock. It traded above $20 two years ago and has steadily gone down. Can anyone bring me up to speed. Why the long decline??
"we expect the anticipated quarterly releases throughout 2017 will fund our clinical development plan through the end of 2017, while also supporting our commercial activities in Europe."
In June we secured $35 million in committed financing with two accredited institutional investors that specialize in biotechnology and medical technology investments. Of the $32.2 million in net proceeds, $3.0 million was unrestricted and immediately available for use. The remaining $29.2 million is held in certain control accounts. The timing of the availability of the balance of the funds from this transaction necessitated the recently announced small fundraise of $1.25 million, which will bridge us to receipt of our first cash release from this committed financing, which we expect in December 2016. Assuming all conditions are satisfied, we expect the anticipated quarterly releases throughout 2017 will fund our clinical development plan through the end of 2017, while also supporting our commercial activities in Europe.
How does it show more contracts? I don't see any evidence of such. Please elaborate.
LIFE LABS PERFORMS OVER 100 MILLION TESTS PER YEAR!!!!
LifeLabs is a Canadian-owned company that has been serving the healthcare needs of Canadians for more than 50 years. Today, LifeLabs performs more than 100 million laboratory tests every year, helping healthcare providers diagnose, treat, monitor and prevent disease in patients.
LifeLabs is strongly committed to continual innovation in testing services. For our patients and healthcare providers, this means we always strive to provide access to the latest specialized clinical tests—to detect cancer for example, to monitor heart disease, identify neurological disorders and pinpoint allergies.
9 more days above $1 and we have Nasdaq Compliance!! That will be a huge day for longs!!
$7 mean price target
Analyst Rating on Transgenomic, Inc. (NASDAQ:TBIO)
Number of analysts are covering this stock and currently stock has got OUTPERFORM rating from 3 analyst of Thomson Reuters, 4 analyst given HOLD rating to the stock and 0 given UNDERPERFORM rating. Analyst’s mean target price for TBIO is $7.00 while analysts mean recommendation is 2.00.
Vericel (VCEL) MACI Approval Puts Profitability Within Reach - Needham & Company
December 14, 2016 3:39 PM
Needham & Company analyst Chad Messer reiterated a Buy rating and $9 price target on Vericel Corporation (NASDAQ: VCEL) the FDA approved Vericel's next generation cell based cartilage repair product MACI ahead of the January 3rd PDUFA. He said the approval puts profitability within reach.
Messer commented, "MACI is a significant advancement over Vericel's currently marketed product Carticel and will carry a broader label as a front line treatment for knee cartilage defects. We anticipate surgeons using Carticel to rapidly convert to MACI. We look for a gradual expansion of Vericel's cartilage repair business as existing surgeons use the product more often and new surgeons add it to their repertoire. We reiterate our Buy rating based on anticipated increased revenue for VCEL in 2017 which could propel Vericel into profitability as early as 4Q:17. We reiterate our Buy rating and view the next year as potentially transformative for VCEL's business"
For an analyst ratings summary and ratings history on Vericel Corporation click here. For more ratings news on Vericel Corporation click here.
Shares of Vericel Corporation closed at $2.60 yesterday.
Huge gap from yesterday's $2.60 close. Never chase a runner up in pre-market. At some point today we will get a significant dip to the low $3's - perhaps even attempt to fill the gap.
Sept 20 it close at .58. The highest we have seen since then is this morning at .15. Huge up gap needs to be filled at .57 which coincides with some short term price targets I have seen
link to bloomberg article on IDXG
http://www.bloomberg.com/press-releases/2016-12-08/interpace-diagnostics-announces-new-aetna-coverage-policy
Zacks gave a strong buy with $4 price target!!!
http://factsreporter.com/2016/12/09/active-volume-stock-sunshine-heart-inc-nasdaqssh/
$2 is the line in the sand. Keeps getting rejected. Shorts want in bad and longs want to keep the party going. Would love to sell a healthy sell of to jump back in. Long-term this is a big winner but love to trade in and out.
The only fear I had was a secondary to take advantage of the run. Boston is getting a lot of shares at .60. Don't know if that is priced in. Could be another offering at much higher prices so I am sitting on the sidelines for a few days. Cashed out and am very happy (and relaxed) for now.
day 3 of big runner usually see moderate to heavy sell off. profit takers and shorts will be out in droves today. I still think this runs to $4-5 by end of December but I sold all my shares pre-market at $1.83. Hope to buy back in if pull back is 25% or more.
With Boston Scientific taking a 15% stake in NVCN, we now have a deep pocket partner that can afford to litigate on our behalf. No way NVCN goes under and the chances of turning over or dramatically reducing prior judgments just got a lot better!
OK I have a limit buy order in a 65 cents. I believe we will see that today.
break out above $3.35 and the next stop is $4 where I set my sell limit. Here she goes!!!
Damn- the Hemp Smart Brain product could be the real deal. A good friend of mine is a psychiatrist at Vanderbilt. I asked him to evaluate the product based on the active ingredients. His reply- "Sounds like they may have a viable product." Hard to get a physician to say anything positive about non prescription supplements so I am encouraged.
I did my own research on each active ingredient and encourage others to do the same. I recently retired from Vanderbilt and may look into their distribution model. I was in sales for many years and this sounds like a good ground floor opportunity. Need to try the product first.
FORMULA
Ingredient Highlights:
Cannabidiol (CBD): The multi-tasking power of Hemp derived CBD offers a broad range of benefits in a water soluble format for advanced bioavailability. The human brain contains cannabinoid receptors that are involved in a variety of physiological processes including mood and memory.
Astaxanthin (AstaReal®): Studies show that this potent antioxidant helps support healthy inflammation levels, reduce DNA damage and battle free radical damage in the brain.
Alpha Glyceryl Phosphoryl Choline A-GPC (AlphaSize®): Improves memory, concentration, learning, recall and mental focus. Supports formation of acetylcholine, a vital neurotransmitter for mental sharpness.
Phosphatidylserine: A multitude of studies have shown that phosphatidyserine can play a critical role in both maintaining key brain functions, including memory, concentration, learning, recall, and focus. Studies also show it may reduce the risk of cognitive dysfunction and dementia in the elderly.
Ashwaganda (Sensoril®): This powerful mood-enhancing adaptogen supports cognition in a number of ways and helps manage how your body handles stress. Numerous clinical studies have shown that Sensoril® helps support stress reduction, energy, mental acuity and concentration.
Rhodiola Rosea: High quality Siberian rhodiola rosea is a powerful adaptogen that helps support sustained energy, concentration, physical performance, and an increased capacity to handle stress and support mood.
Bacopa Monnieri (Bacognize®): Used in traditional medicine for thousands of years, multiple published trials found that bacopa glycosides showed significant improvement in cognitive function, including memory, focus, and attention.
Piper Nigrum, Fruit (BioPerine®): BioPerine® is a patented extract of piperine (black pepper) with unique thermonutrient properties to help ensure optimal potency and bioavailability of nutritional compounds.
Huperzia Serrata (Huperzine-A): Has been shown to maintain healthy levels of acetylcholine and is being researched for a broad range of neuroprotective effects including promoting optimal memory function.
Green Tea Extract (70% EGCG): Recent studies indicate green tea extract increases the brain’s effective connectivity, and thus improvement in cognitive performance.
L-Theanine: Is the predominant amino acid of green tea that produces the brain calming effects by helping to increase levels of serotonin, dopamine, and alpha-brain waves, helping put you in a better mood.
Turmeric Complex: Studies have shown that curcumin, an active component in turmeric, may help support brain neurogenesis (development of new brain cells) and demonstrates neuroprotective actions thought to be due its antioxidant and healthy inflammation support properties.
Trace Minerals: Our trace mineral blend contains a full spectrum of naturally occurring elements including magnesium. Magnesium participates in more than 300 metabolic reactions, many of which are needed for normal brain function.
Vitamin D3: Vitamin D receptors have been found in many parts of the brain and is believed to play a role in mood and emotional health.
Vitamin B6: Participates in more than 140 enzymatic reactions, including neurotransmitter function, among many others.
Vitamin B9: Is crucial for healthy brain function and plays an important role in mental and emotional health.
Vitamin B12: Plays an essential role supporting a variety of neurological functions including its role in encouraging healthy cognition, memory, and emotional function.
Can't find the answer to this one? How does club Harmoneous deliver its marijuana? The postal service is a federal service and that would be a problem. Anyone know the answer to this all important question?
On Nov. 22, 2016, Veterans Affairs Canada announced a new reimbursement policy for veterans using medical cannabis. While veterans can now be reimbursed for medical cannabis extracts, the daily reimbursement limit dropped from 10 grams to 3 grams.
“We consulted with Veterans, their advocates, stakeholders, medical experts and reviewed existing research on using marijuana for medical purposes and developed a balanced policy,” said The Honourable Kent Hehr, Minister of Veterans Affairs and Associate Minister of National Defence, in a statement.
A recent study by MedReleaf, a medical cannabis producer licensed by Health Canada, found that a dosage of 9.4 grams of medical cannabis per day improved outcomes for patients with post-traumatic stress disorder by 50-60%.
According to Dr. Paul Smith, the study’s head researcher, “There is no one-size-fits-all approach to effective cannabis dosing but I believe that when veterans get VAC coverage for cannabis oils and capsules, we’ll see more veterans turn to this treatment.”
The 3-gram limit goes into effect after May 21, 2017, with a reimbursement rate of up to $8.50 per gram.
yahoo finance- $67,000 cash $280 million in debt. This is a house of cards people. Anyone not selling pre-market or at the open will regret it in my opinion. No justification for a 2000% + increase. A run from $4 to $100 on no real news is a gift from the gods.
10-k just out and with dreaded "going concern" warning along with about 100 other possible things that can go wrong. I'm outa here after reading it. Good luck to remaining longs.
when can we expect Nasdaq compliance news?
9 more days in a row closing above $1 gets us Nasdaq compliance by Oct. 31 and just before earnings. If that happens, expect a nice pop Nov. 1. Nov. 3 is expected be good as well.
That "insider" sold about 2% of their 68 million shares. No worries.
C'mon guys- how can you say this is a different collaboration than the one referenced Oct. 13. Read the Investor Hub news release on AMRS on Oct. 13. The numbers and wording are identical. Someone back me up here. I'm long but don't like excessive and redundant pumping. Makes me think P and D.
Yes I am serious- following is from Oct. 13. Tell me there is no difference?
myris Agrees to Collaboration Terms with Leading Global Food Ingredients and Nutraceuticals Partner
GlobeNewswire•October 13, 2016
EMERYVILLE, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (AMRS), the industrial bioscience company, today announced that it has executed a Memorandum of Understanding for a transformative strategic collaboration with a partner that is a leader in food ingredients and nutraceuticals. Upon required approval and execution of definitive agreements with this new partner, Amyris expects to receive cash representing a short-term collaboration investment of $10 million, an equity investment of up to $20 million at $1.40 per share, $100 million in annual revenue starting in 2017 connected to the production and cost improvement of fermentation molecules, and participation in the partner’s industrial fermentation facilities in Asia.
This relationship follows a series of significant partnerships Amyris has announced in recent months, including a partnership with a separate company in the nutraceuticals space that was announced on September 30, 2016.
“We’re very pleased with the opportunity to partner with one of the leading nutraceutical and food ingredient suppliers in the world. Our current annual revenue run rate of over $100 million combined with the $100 million of annual revenue we expect from this partnership starting in 2017, should help us deliver stronger than expected growth in 2017 and beyond,” said John Melo, Amyris President & CEO.
Continued Melo, “We anticipate that this collaboration will support our short-term results with an expected $10 million in 2016 collaboration funding. The combination of the strong pipeline of products from our new partner, the short-term collaboration payment and anticipated revenue for 2017 and beyond makes this a transformative relationship for our business. We believe the combination of this collaboration and the strong momentum in our underlying business will provide us with what we believe is the largest pipeline of contracted fermentation-based molecules in the world, deliver the highest revenue growth rate in our sector and make us one of the fastest-growing companies in nutraceuticals and food ingredients.”
“We are very pleased with the strong momentum we are realizing from becoming the must-have technology for our partners.”
Both parties have agreed to keep the partner’s name confidential for now. The collaboration is subject to completion of definitive agreements and the obtaining of required approvals. Amyris expects this to be completed by the beginning of December 2016.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients and consumer products. The company is delivering its No Compromise® products in focused markets, including specialty and performance chemicals, fragrance ingredients, and cosmetic emollients. More information about the company is available at www.amyris.com.
That is just a reprint of news that came out last week.
Its been verified- sale of non-essential assets on top of huge infusion of cash from partners eliminates the need for any dilution!!
Today from SA-
AMRS's share price is up significantly since my initial analysis.
Amyris has since made deals to secure its future.
I expect further upside.
On August 16th I published a bullish case for Amyris (NASDAQ:AMRS). Since then the stock has risen from near $0.40 per share to over $0.80 per share. Such price growth has been justified by a number of new announcements by the company:
Amyris finalized the agreement with Ginkgo, securing funding for the company and accelerating bringing new molecules to market. They also amended their agreement to extend some of the company's debt from 2017 to up to 2019.
Amyris signed an agreement with a nutraceutical company securing $25 million in funding, an optional $5 million investment and a product supply agreement that will increase Amyris's revenue by $40 million in 2017 and eventually grow to $70 million a year.
Finally, Amyris agreed to the terms of a deal with another nutraceutical company, getting $10 million in collaboration revenue, an equity investment of up to $20 million at $1.4/share (75% premium to market price), and $100 million in annual revenue starting in 2017.
The last bit is especially significant. It essentially doubles the current revenue run rate for the company. With gross margins at 50-60% it will also move the company significantly closer to profitability. It also makes the managements expectations of positive cash flow in 2017 quite credible.
With the asset sale coming later this year, the company has no need for dilutive funding. Their revenues are set to increase dramatically in 2017. With more deals to be announced soon, I expect the $1.40 per share purchase by their partner to be considered a bargain.
news this morning- Suntrust Robinson analysts downgrades stock to neutral Price target $15
However- RBC cuts to $49 from $74 and Piper Jaffray cuts to $22 from $57. 5 of 7 brokerages rate the stock buy or higher and 2 rate hold. Median price target $55
Sounds like there is a good chance this stock is still viable with a lot or room to run from pre-market of around $15. Wouldn't be surprised to see it retrace 50% of the sell off taking it back to high $20's today.